search for


All categories

Intellectual property system

  Implement intellectual property strategy to support global presence

  Borui Medicine attaches great importance to the protection of intellectual property rights, and is one of the first batch of high-tech pharmaceutical enterprises in Suzhou Industrial Park to pass the acceptance test of the "Conformance Standard" project. Each breakthrough in the company's research and development will be protected in the form of a patent. More than 300 invention patents have been applied. As of March 31, 2019, 89 invention patents have been authorized at home and abroad. Entecavir, which avoids the original research patent route, not only won the first imitation in China, but also successfully challenged the patent in the United States, obtaining a 180-day market exclusivity period. The implementation of the patent strategy has broken the product life cycle of competitors, enabled the company's products to obtain better market opportunities and shares, and also protected the company's core secrets, which is one of Borui Medicine's core strategies. With the in-depth implementation of the intellectual property strategy, in recent years, Borui Pharmaceutical's investment in the field of intellectual property has gradually entered the harvest period, and has successively obtained "Suzhou Industrial Park High-Value Patents" and "Suzhou Enterprise Intellectual Property Ascent Strategy" Jiangsu Province Intellectual Property Strategy Promotion Enterprise "," China Patent Excellence Award "and" National Intellectual Property Advantage Enterprise "and other honors have strongly supported the company's expansion in the international market.



Back to top ▲

Borui Medicine


Building C25-28, 218 Xinghu Road, Suzhou Industrial Park, Jiangsu Province, China

Borui Medicine




Borui Medicine


Copyright: BrightGene Bio-Medical Technology Co., Ltd.   · Suzhou Su ICP No. 18,000,014           

Copyright: Borui Biomedical (Suzhou) Co., Ltd. 

Powered by